Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26921062 | 0.97 | TSHR (0.39) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL10029816 | 0.97 | TSHR (0.39) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL10301180 | 0.95 | MEN1 (0.39) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL403336 | 0.95 | TSHR (0.41) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL14867188 | 0.93 | MEN1 (0.40) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL26254168 | 0.93 | MEN1 (0.32) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL14867187 | 0.93 | MEN1 (0.40) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL10301169 | 0.93 | MEN1 (0.40) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL13330245 | 0.92 | MEN1 (0.32) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL13330243 | 0.92 | MEN1 (0.32) | TSHRMEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210835-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | LIMEWAY PHARMA DESIGN LTD (GB) | 2023-07-06 | — | — | US | disclosed |
| US-20180028438-A1 | TOPICAL FORMULATION | LIMEWAY PHARMA DESIGN LIMITED (GB) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028438-A1 | TOPICAL FORMULATION | CERS2, SGMS1, SGMS2 | TSHR 4410/4885MEN1 1281/4885KMT2A 352/4885 |
| US-20230210835-A1 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | CUTA, SGMS1, CERS2 | TSHR 4805/4885MEN1 1469/4885KMT2A 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.